XSTOLIPUM
Market cap22mUSD
Dec 23, Last price
11.90SEK
1D
-7.75%
1Q
-12.50%
IPO
-52.40%
Name
Lipum AB (publ)
Chart & Performance
P/E
—
P/S
4,762.78
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
425.89%
Rev. gr., 5y
-20.63%
Revenues
53k
Net income
-37m
L-2.79%
CFO
-36m
L-31.07%
Profile
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of pediatric rheumatism and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116. The company was founded in 2010 and is headquartered in Umeå, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | 53 | ||||||
Cost of revenue | 26,001 | 61,432 | 96,648 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (25,948) | (61,432) | (96,648) | ||||
NOPBT Margin | |||||||
Operating Taxes | 160 | 150 | |||||
Tax Rate | |||||||
NOPAT | (25,948) | (61,592) | (96,798) | ||||
Net income | (37,178) -2.79% | (38,245) -27.02% | (52,406) 147.93% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 15,276 | 39,161 | 85,701 | ||||
BB yield | -28.07% | -44.19% | -111.51% | ||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | 1,761 | 1,661 | 1,566 | ||||
Deferred revenue | |||||||
Other long-term liabilities | (1,661) | 1,560 | |||||
Net debt | (8,465) | (31,176) | (45,487) | ||||
| Cash flow | |||||||
Cash from operating activities | (36,126) | (52,406) | (34,296) | ||||
CAPEX | (188) | (60) | |||||
Cash from investing activities | (188) | (60) | |||||
Cash from financing activities | 13,703 | 38,250 | 76,909 | ||||
FCF | (26,096) | (61,641) | (96,534) | ||||
| Balance | |||||||
Cash | 10,226 | 32,837 | 47,053 | ||||
Long term investments | |||||||
Excess cash | 10,223 | 32,837 | 47,053 | ||||
Stockholders' equity | (161,201) | (124,438) | (87,165) | ||||
Invested Capital | 167,534 | 153,650 | 118,017 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 8,346 | 6,353 | 4,154 | ||||
Price | 6.52 -53.26% | 13.95 -24.59% | 18.50 | ||||
Market cap | 54,416 -38.60% | 88,629 15.32% | 76,852 | ||||
EV | 45,951 | 57,453 | 31,365 | ||||
EBITDA | (25,908) | (61,421) | (96,648) | ||||
EV/EBITDA | |||||||
Interest | 169 | 150 | |||||
Interest/NOPBT | |||||||